Skip to main content
SpringerLink
Log in

Ewing’s sarcoma family of tumors

  • Educational Review
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gurney JG, Davis S, Severson RK, et al. Trends in cancer incidence among children in the U.S. Cancer. 1996;78:532–41.

    Article  Google Scholar 

  2. Fraumeni JF Jr, Glass AG. Rarity of Ewing's sarcoma among U.S. Negro children. Lancet. 1980;1:366–7.

    Google Scholar 

  3. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors: A subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994;331:294–9.

    Article  PubMed  CAS  Google Scholar 

  4. Ewing J. Diffuse endothelioma of bone. Proc NY Pathol Soc. 1921;21:17–24.

    Google Scholar 

  5. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: Final results of the Cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol. 2001;19:1818–29.

    PubMed  CAS  Google Scholar 

  6. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998;9:275–81.

    Article  PubMed  CAS  Google Scholar 

  7. Thiele CJ. Biology of pediatric peripheral neuroectodermal tumors. Cancer Metastasis Rev. 1991;10:311–9.

    Article  PubMed  CAS  Google Scholar 

  8. O'Regan S, Diebler MF, Meunier FM, et al. Ewing's sarcoma cell line showing some, but not all, of the traits of a cholinergic neuron. J Neurochem. 1995;64:69–76.

    Article  PubMed  Google Scholar 

  9. Navarro S, González-Devesa M, Fernández Izquierdo A, et al. Scanning electron microscopic evidence for neural differentiation in Ewing's sarcoma cell lines. Virchows Arch. 1990;416:383–91.

    Article  CAS  Google Scholar 

  10. Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res. 2004;64:8213–21.

    Article  PubMed  CAS  Google Scholar 

  11. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest. 1990;86:1806–14.

    Article  PubMed  CAS  Google Scholar 

  12. Toretsky JA, Thaakar M, Eskenazi AE, et al. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Research. 1999;59:5745–50.

    PubMed  CAS  Google Scholar 

  13. Bailly R-A, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol. 1994;14:3230–41.

    PubMed  CAS  Google Scholar 

  14. de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol. 2000;18:204–13.

    PubMed  Google Scholar 

  15. Sorensen PHB, Lessnick SL, López-Terrada D, et al. A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994;6:146–51.

    Article  PubMed  CAS  Google Scholar 

  16. Zucman J, Melot T, Desmaze C, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 1993;12:4481–7.

    PubMed  CAS  Google Scholar 

  17. Perlman EJ, Dickman PS, Askin FB, et al. Ewing's sarcoma-Routine diagnostic utilization of MIC2 analysis: A Pediatric Oncology Group/Childrens Cancer Group Intergroup Study. Hum Pathol. 1994;25:304–7.

    Article  PubMed  CAS  Google Scholar 

  18. Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis: Results and comparisons of two Intergroup Ewing's Sarcoma Studies. Cancer. 1990;66:887–93.

    Article  PubMed  CAS  Google Scholar 

  19. Kinsella TJ, Misser JS, Waller B, et al. Long-term followup of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiot Oncol Biol Phys. 1991;20:389–96.

    Article  CAS  Google Scholar 

  20. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18:3108–14.

    PubMed  CAS  Google Scholar 

  21. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol. 2003;21:3423–30.

    Article  PubMed  CAS  Google Scholar 

  22. Paulussen M, Arhens S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol. 1998;16:3044–52.

    PubMed  CAS  Google Scholar 

  23. Craft AW, Cotterill S, Malcolm A, et al. Ifosfamide containing chemotherapy in Ewing's sarcoma: the Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol. 1998;16:3628–33.

    PubMed  CAS  Google Scholar 

  24. Bacci G, Ferrari F, Bertoni F, et al. Prognostic factors in non-metastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000; 18:4–11.

    PubMed  CAS  Google Scholar 

  25. Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80:1020–33.

    Article  PubMed  CAS  Google Scholar 

  26. de Alava E, Lozano MD, Patino A, et al. Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. Diagn Mol Pathol. 1998;7:152–7.

    Article  PubMed  Google Scholar 

  27. Avigad S, Cohen IJ, Zilberstein J, et al. The predictive potential of molecular detection in the non-metastatic Ewing family of tumors. Cancer. 2004;100:1053–8.

    Article  PubMed  Google Scholar 

  28. Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol. 2003;21:85–91.

    Article  PubMed  Google Scholar 

  29. West DC, Grier HC, Swallow MM, et al. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol. 1997;15:583–8.

    PubMed  CAS  Google Scholar 

  30. de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol. 1998;16: 1248–55.

    PubMed  Google Scholar 

  31. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol. 1996;14:1245–51.

    Google Scholar 

  32. Ginsberg JP, de Alava E, Landanyi M, et al. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol. 1999;17:1809–14.

    PubMed  CAS  Google Scholar 

  33. Hattinger CM, Potscherg U, Tarkkanen M, et al. Prognostic impact of chromosomal aberrrations in Ewing tumors. Br J Cancer. 2002;86:1763–9.

    Article  PubMed  CAS  Google Scholar 

  34. Hayes FA, Thompson El, Meyer WH, et al. Therapy for localized Ewing's sarcoma of bone. J Clin Oncol. 1989;7:208–13.

    PubMed  CAS  Google Scholar 

  35. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer. 1988;61:23–32.

    Article  PubMed  CAS  Google Scholar 

  36. Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: A feasibility study at St Jude Children's Research Hospital. J Clin Oncol. 1999;17:180–90.

    PubMed  CAS  Google Scholar 

  37. Nesbit ME, Gehan EA, Burgert EO, et al. Multimodal therapy for the management of primary, non-metastatic Ewing's sarcoma of bone: A long-term follow-up of the first intergroup study. J Clin Oncol. 1990;8:1664–74.

    PubMed  Google Scholar 

  38. Burgert EO, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of non-pelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol. 1990;8:1514–24.

    PubMed  Google Scholar 

  39. Craft AW, Cotterill SJ, Bullimore JA, et al. A long-term result from the first UKCCSG Ewing's tumor study (ET-1). Eur J Cancer. 1997;33:1061–9.

    Article  PubMed  CAS  Google Scholar 

  40. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348 694–701.

    Article  PubMed  CAS  Google Scholar 

  41. Craft AV, Paulussen M, Douglas C, et al. EICESS-92 early results of an international Ewing's tumor study. Med Pediatr Oncol. 2000;35:191 (Abstract)

    Google Scholar 

  42. Rosito P, Manccini AF, Rondelli R, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sacroma of bone: A preliminary report of 6 years of experience. Cancer. 1999; 86:421–8.

    Article  PubMed  CAS  Google Scholar 

  43. Meyer WH, Kun L, Marina N, et al. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J Clin Oncol. 1992;10:1737–42.

    PubMed  CAS  Google Scholar 

  44. Granowetter L, Womer R, Devidas M, et al. Comparison of dose intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: a Pediatric Oncology Group-Children's Cancer Group Phase III trial. Med Pediatr Oncol. 2001;37:172 (Abstract).

    Google Scholar 

  45. Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol. 1995;13:2796–804.

    PubMed  CAS  Google Scholar 

  46. Kushner BH, Heller G, Cheung NK, et al. High risk of leukaemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol. 1998;16:3016–20.

    PubMed  CAS  Google Scholar 

  47. Miser J, Krailo M, Smith M, et al. Secondary leukemia (SL) or myelodisplastic syndrome (MDS) following therapy for Ewing's sarcoma (ES) Proc Ann Meet Am Soc Clin Oncol. 1997;16:518 (Abstract).

    Google Scholar 

  48. Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: Results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003;55:168–77.

    Article  PubMed  Google Scholar 

  49. Krasin MJ Rodríguez-Galindo C, Davidoff AM, et al. Efficacy of combined surgery and irradiation for localized Ewing's sarcoma family of tumors. Pediatr Blood Cancer. 2004;43:229–36.

    Article  PubMed  Google Scholar 

  50. Donaldson SS, Torrey m, Link MP, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: End results of POGG#8346. Int J Radiat Oncol Biol Phys. 1998;42:125–35.

    Article  PubMed  CAS  Google Scholar 

  51. Kuttesch JF, Wesler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: Radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996;14:2818–25.

    Google Scholar 

  52. Shankar AG, Pinkerton CR, Atra A, et al. Local therapy and other factors influencing site of relapse inpatients with localized Ewing'sarcoma. Eur J Cancer. 1999;35:1698–704.

    Article  PubMed  CAS  Google Scholar 

  53. Donaldson S. Ewing sarcoma: Radiation dose and target volume. Pediatr Blood Cancer: 2004:42:471–6.

    Article  PubMed  Google Scholar 

  54. Dunst J, Jurgens H, Sauer R, et al. Radiation therapy in Ewing's sarcoma: An update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995;32:919–30.

    Article  PubMed  CAS  Google Scholar 

  55. Dunst J, Schuck A. Role of radiotherapy in Ewing tumors. Pediatr Blood Cancer. 2004;42:465–70.

    Article  PubMed  Google Scholar 

  56. Pinkerton CR, Bataillard A, Guillo S, et al. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer. 2001;37:1338–44.

    Article  PubMed  CAS  Google Scholar 

  57. Miser JS, Krailo M, Meyers P, et al. Metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone: Failure of new regimens to improve outcome. Proc Ann Meet Am Soc Clin Oncol. 1996; 15:467 (Abstract).

    Google Scholar 

  58. Felgenhauer J, Hawkins D, Pendergrass T, et al. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. Med Pediatr Oncol. 2000;34:29–38.

    Article  PubMed  CAS  Google Scholar 

  59. Madero L, Muñoz A, Sanchez de Toledo J, et al. Megatherapy in children with high-risk Ewing's sarcoma in first complete remission. Bone Marrow Transplant. 1998;21:795–9.

    Article  PubMed  CAS  Google Scholar 

  60. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol. 1993;11:1482–8.

    PubMed  CAS  Google Scholar 

  61. Atra A, Whelan JS, Calvagne V, et al. High-dose busulfan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant. 1997;20:843–6.

    Article  PubMed  CAS  Google Scholar 

  62. Kushner, BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering Experience and a literature review. J Clin Oncol. 2001;19:870–80.

    PubMed  CAS  Google Scholar 

  63. Meyers PA, Krailo MD, Landanyi M, et al. High dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol. 2001;19:2812–20.

    PubMed  CAS  Google Scholar 

  64. Ladenstein R, Hartmann O, Pinkerton R, et al. Multivariate and matched pair analysis on high-risk Ewing's tumours (ET) patients treated by megatherapy (MGT) and stem cell reinfusion (SCR) in Europe. Proc Ann Meet Am Soc Clin Oncol. 1999;18:555 (Abstract)

    Google Scholar 

  65. Davies SM, DeFor TE, Weigel BJ, et al. High dose busulfan-based chemotherapy with autologous stem cell transplantation (ASCT) for high risk Ewing's sarcoma family of tumors. Proc Ann Meet Am Soc Clin Oncol. 2001;20:364 (Abstract).

    Google Scholar 

  66. Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup Study EICESS-Stem-Cell Transplant Programs at Dusseldorf University Mediacal Center, Germany, and St Anna Kinderspital, Vienna, Austria. Ann Oncol. 2000;11:1451–62.

    Article  PubMed  CAS  Google Scholar 

  67. Burdach S, Meyer-Bahlburg A, Laws HJ, et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: Results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol. 2003;21:3072–8.

    Article  PubMed  CAS  Google Scholar 

  68. Hawkins D, Barnett T, Bensinger W, et al. Busulfán, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatric Oncol. 2000;34:328–37.

    Article  CAS  Google Scholar 

  69. Rodríguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing's sarcoma family of tumors: Current status and outlook for the future. Med Pediatr Oncol. 2003;40:276–87.

    Article  PubMed  Google Scholar 

  70. Benini S, Manara MC, Baldini N, et al. Inhibition of Insulin-like growth factor I receptor increases the antitumor activity of doxorrubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res. 2001;7:1790–7.

    PubMed  CAS  Google Scholar 

  71. Chansky HA, Barahmand-pour F, Mei Q, et al. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cellsin vitro. J Orthop Res. 2004;22:910–7.

    Article  PubMed  CAS  Google Scholar 

  72. Ricotti E, Fagioli F, Garelli E, et al. C-kit expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood. 1998;91:2397–405.

    PubMed  CAS  Google Scholar 

  73. González I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewin tumor cells mediated by stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorrubicin-induced apoptosis. Clin Cancer Res. 2004;10:751–61.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidad de Oncología Pediátrica. Departamento de Pediatría, Hospital Central de Asturias, C/Celestino Villamil s/n, 33006, Oviedo, Asturias

    María Jesús Antuña García

Authors
  1. María Jesús Antuña García
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to María Jesús Antuña García.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antuña García, M.J. Ewing’s sarcoma family of tumors. Clin Transl Oncol 7, 262–269 (2005). https://doi.org/10.1007/BF02710174

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02710174

Keywords

Search

Navigation